Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription


1 Am J Clin Pathol
6 Am J Hematol
5 Blood
3 Bone Marrow Transplant
2 Cancer
1 Cancer Res
10 Hematol Oncol Clin North Am
1 Int J Hematol
2 Leuk Lymphoma
1 Leuk Res
9 Leukemia
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Clin Pathol

  1. HAUSER RG, Esserman D, Beste LA, Ong SY, et al
    A Machine Learning Model to Successfully Predict Future Diagnosis of Chronic Myelogenous Leukemia With Retrospective Electronic Health Records Data.
    Am J Clin Pathol. 2021 Jun 29. pii: 6310949. doi: 10.1093.
    PubMed         Abstract available

    Am J Hematol

  2. MOIGNET A, Pastoret C, Cartron G, Coppo P, et al
    Ruxolitinib for refractory large granular lymphocyte leukemia.
    Am J Hematol. 2021 Jun 16. doi: 10.1002/ajh.26275.

  3. GANGAT N, Guglielmelli P, Szuber N, Begna KH, et al
    Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
    Am J Hematol. 2021;96:781-789.
    PubMed         Abstract available

  4. HAYDU JE, Flamand Y, Vedula RS, Versluis J, et al
    Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction.
    Am J Hematol. 2021;96:E259-E262.

  5. JENTZSCH M, Grimm J, Bill M, Brauer D, et al
    Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2021;96:E237-E239.

  6. JOSHI SK, Sharzehi S, Pittsenbarger J, Bottomly D, et al
    A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
    Am J Hematol. 2021;96:E226-E229.

  7. OZGA M, Blachly J, Eisfeld AK, Grieselhuber N, et al
    Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
    Am J Hematol. 2021;96:E223-E225.


  8. LEONARD JT, Kosaka Y, Malla P, LaTocha D, et al
    Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
    Blood. 2021;137:939-944.
    PubMed         Abstract available

  9. SERA Y, Nakata Y, Ueda T, Yamasaki N, et al
    UTX maintains the functional integrity of the murine hematopoietic system by globally regulating aging-associated genes.
    Blood. 2021;137:908-922.
    PubMed         Abstract available

  10. QAYED M, Ahn KW, Kitko CL, Johnson MH, et al
    A validated pediatric disease risk index for allogeneic hematopoietic cell transplantation.
    Blood. 2021;137:983-993.
    PubMed         Abstract available

  11. HERGOTT CB, Pozdnyakova O
    Beware the "other AML": hepatic angiomyolipoma with extensive extramedullary hematopoiesis.
    Blood. 2021;137:860.

  12. MEIER-ABT F, Lu J, Cannizzaro E, Pohly MF, et al
    The Protein Landscape of Chronic Lymphocytic Leukemia (CLL).
    Blood. 2021 Jun 29. pii: 476272. doi: 10.1182/blood.2020009741.
    PubMed         Abstract available

    Bone Marrow Transplant

  13. GEVA M, Pryce A, Shouval R, Fein JA, et al
    High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2021 Jun 29. pii: 10.1038/s41409-021-01377.
    PubMed         Abstract available

  14. CHO BS, Min GJ, Park SS, Park S, et al
    Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11.
    Bone Marrow Transplant. 2021 Jun 28. pii: 10.1038/s41409-021-01384.
    PubMed         Abstract available

  15. BRUZZESE A, Assanto GM, Diverio D, Quattrocchi L, et al
    Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience.
    Bone Marrow Transplant. 2021;56:1455-1457.


  16. SAXENA K, Herbrich SM, Pemmaraju N, Kadia TM, et al
    A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia.
    Cancer. 2021 Jun 25. doi: 10.1002/cncr.33690.
    PubMed         Abstract available

  17. VENUGOPAL S, Shoukier M, Konopleva M, Dinardo CD, et al
    Outcomes in patients with newly diagnosed TP53-mutated acute myeloid leukemia with or without venetoclax-based therapy.
    Cancer. 2021 Jun 28. doi: 10.1002/cncr.33675.
    PubMed         Abstract available

    Cancer Res

  18. MAIFREDE S, Le BV, Nieborowska-Skorska M, Golovine K, et al
    TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors.
    Cancer Res. 2021 Jul 2. pii: 0008-5472.CAN-20-3761.
    PubMed         Abstract available

    Hematol Oncol Clin North Am

  19. NG A, Chiorazzi N
    Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic Leukemia.
    Hematol Oncol Clin North Am. 2021;35:665-685.
    PubMed         Abstract available

  20. VLACHONIKOLA E, Sofou E, Chatzidimitriou A, Stamatopoulos K, et al
    The Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical Implications.
    Hematol Oncol Clin North Am. 2021;35:687-702.
    PubMed         Abstract available

  21. CHERNG HJ, Jain N
    First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
    Hematol Oncol Clin North Am. 2021;35:725-738.
    PubMed         Abstract available

  22. DING W
    The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond.
    Hematol Oncol Clin North Am. 2021;35:739-759.
    PubMed         Abstract available

  23. LASICA M, Tam CS
    Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
    Hematol Oncol Clin North Am. 2021;35:761-773.
    PubMed         Abstract available

  24. THOMPSON MC, Mato AR
    Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
    Hematol Oncol Clin North Am. 2021;35:793-806.
    PubMed         Abstract available

  25. LAMPSON BL, Brown JR
    The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.
    Hematol Oncol Clin North Am. 2021;35:807-826.
    PubMed         Abstract available

  26. SUN C, Wiestner A
    Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?
    Hematol Oncol Clin North Am. 2021;35:827-845.
    PubMed         Abstract available

  27. SHADMAN M, Maloney DG
    Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.
    Hematol Oncol Clin North Am. 2021;35:847-862.
    PubMed         Abstract available

  28. BROWN JR
    Chronic Lymphocytic Leukemia: So Much Progress, Still Challenges Ahead.
    Hematol Oncol Clin North Am. 2021;35:xiii-xiv.

    Int J Hematol

  29. LV K, Cai C, Chen J, Xu M, et al
    Prognostic value of lymphoid marker CD7 expression in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in first morphological complete remission.
    Int J Hematol. 2021 Jun 26. pii: 10.1007/s12185-021-03182.
    PubMed         Abstract available

    Leuk Lymphoma

  30. STAHL M, Narendra V, Jee J, Derkach A, et al
    Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality.
    Leuk Lymphoma. 2021 Jun 28:1-9. doi: 10.1080/10428194.2021.1885664.
    PubMed         Abstract available

  31. JIANG H, Liu XH, Kong J, Wang J, et al
    Interferon-alpha as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia.
    Leuk Lymphoma. 2021 Jul 1:1-8. doi: 10.1080/10428194.2021.1948027.
    PubMed         Abstract available

    Leuk Res

  32. KONDYLI M, Tremblay DE, Rezgui A, Serfaty SA, et al
    Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
    Leuk Res. 2021;109:106650.


  33. WIERDA WG, Rawstron A, Cymbalista F, Badoux X, et al
    Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.
    Leukemia. 2021 Jun 24. pii: 10.1038/s41375-021-01241.
    PubMed         Abstract available

  34. SHORT NJ, Kantarjian H, Jabbour E
    Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.
    Leukemia. 2021 Jun 25. pii: 10.1038/s41375-021-01277.
    PubMed         Abstract available

  35. TOKSVANG LN, Grell K, Nersting J, Degn M, et al
    DNA-thioguanine concentration and relapse risk in children and young adults with acute lymphoblastic leukemia: an IPD meta-analysis.
    Leukemia. 2021 Jun 26. pii: 10.1038/s41375-021-01182.
    PubMed         Abstract available

  36. RENNEVILLE A, Patnaik MM, Chan O, Padron E, et al
    Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.
    Leukemia. 2021 Jun 26. pii: 10.1038/s41375-021-01330.
    PubMed         Abstract available

  37. BEHNERT A, Meyer J, Parsa JY, Hechmer A, et al
    Exploring the genetic and epigenetic origins of juvenile myelomonocytic leukemia using newborn screening samples.
    Leukemia. 2021 Jun 28. pii: 10.1038/s41375-021-01331.

  38. TAJ MM, Moorman AV, Hamadeh L, Petit A, et al
    Prognostic value of Oncogenetic mutations in pediatric T Acute Lymphoblastic Leukemia: a comparison of UKALL2003 and FRALLE2000T protocols.
    Leukemia. 2021 Jun 28. pii: 10.1038/s41375-021-01334.

  39. THOMAS KR, Allenspach EJ, Camp ND, Wray-Dutra MN, et al
    Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice.
    Leukemia. 2021 Jun 30. pii: 10.1038/s41375-021-01326.
    PubMed         Abstract available

  40. SIMONETTI G, Mengucci C, Padella A, Fonzi E, et al
    Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.
    Leukemia. 2021 Jun 30. pii: 10.1038/s41375-021-01318.
    PubMed         Abstract available

  41. BOER JM, Valsecchi MG, Hormann FM, Antic Z, et al
    Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study.
    Leukemia. 2021 Jul 1. pii: 10.1038/s41375-021-01333.

    PLoS One

  42. PONVILAWAN B, Kungwankiattichai S, Charoenngam N, Owattanapanich W, et al
    Is stem cell transplantation still needed for adult Philadelphia chromosome-positive acute lymphoblastic leukemia receiving tyrosine kinase inhibitors therapy?: A systematic review and meta-analysis.
    PLoS One. 2021;16:e0253896.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.